Anti-PCSK9 monoclonal antibodies, also called the biological treatment for hypercholesterolemia or, simply, PCSK9-inhibitors (PCSK9-i), introduced the possibility of decreasing LDL-C levels by 40–60% when used additively to the maximum tolerated dose of lipid-lowering drugs [25]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.